Drug Patents Expiring in 2043
1. Auvelity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11717518 | AXSOME | Bupropion dosage forms with reduced food and alcohol dosing effects |
Jan, 2043
(19 years from now) | |
| US11730706 | AXSOME | Treatment of depression in certain patient populations |
Jan, 2043
(19 years from now) | |
| US11752144 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Feb, 2043
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and buproprion in combination to treat major depressive disorder; Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUVELITY family patents
2. Brukinsa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11786531 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
| Orphan Drug Exclusivity (ODE) | Sep 14, 2028 |
| New Indication (I) | Sep 14, 2024 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 2023-11-15
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) receiving a moderate cyp3a inducer; Treatment of adult patients with waldenstrom's macroglobulin...
Dosage: CAPSULE;ORAL
BRUKINSA family patents
3. Igalmi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11806334 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 5, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual or buccal administration in patients with severe hepatic impairment
Dosage: FILM;BUCCAL, SUBLINGUAL
IGALMI family patents